Overview

• Pfizer will give Medicaid most‑favored‑nation pricing and said new U.S. drug launches will be priced at parity with other developed countries.
• A federal TrumpRx portal is planned for 2026 to route consumers to manufacturers’ direct sales, with Pfizer citing average 50% discounts and examples over 80% on select drugs.
• The agreement grants Pfizer a three‑year exemption from threatened pharmaceutical tariffs contingent on roughly $70 billion in U.S. manufacturing and research investment.
• The deal does not include Medicare or private insurers, so immediate savings are expected to accrue mainly to state and federal Medicaid budgets rather than most patients at the pharmacy counter.
• Officials say similar agreements with other drugmakers are being pursued as the administration leverages potential tariffs, including previously threatened 100% duties, to secure voluntary concessions.